Gauging the magnitude of missed opportunity for ovarian cancer prevention
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-Aug-2025 08:11 ET (14-Aug-2025 12:11 GMT/UTC)
Researchers have spent years taking apart one of the world’s simplest microbes, Mycoplasma pneumoniae, piece by piece, and created a detailed list of what molecular parts the living cell can and cannot do without, knowledge that could accelerate the development of “living medicines” built from this very microbe. Their efforts have revealed how much real estate engineers have to edit and repurpose the bacterium for therapeutic purposes, for example to combat antibiotic resistance or cancer. The study, published today in Molecular Systems Biology, is the most comprehensive “essentiality map” for any living organism built to date.
Scientists discovered that three TCF7-expressing tumor-reactive T cell subpopulations exhibit selective expansion during ovarian tumor-infiltrating T cell production ex vivo. CD8+ TCF7+ Tpex cells demonstrate self-renewal capacity and generate stem-like progenies. CD8+ TCF7+ Tpex and CD4+ TCF7+ Tfh cells are both marked by the co-expression of CCR7 and CD200. Selectively expanding CCR7+CD200+ T cells enriches stem-like, tumor-reactive T cells, enabling precise ex vivo expansion of therapeutic T cell subpopulations for adoptive cell therapy.